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  EVIDENCE-BASED ANSWER 
Long-term use of proton pump inhibitors (PPIs) appears safe, resulting in no clinically relevant adverse effects 
(strength of recommendation: B, based on nonsystematic reviews, cohort studies, or low-quality randomized 
controlled trials). No evidence clearly links PPIs to gastric cancer or carcinoid, enteric infections, or significant 
nutrient malabsorption. 
  EVIDENCE SUMMARY 
The long-term safety of PPIs is not completely known. There are 5 PPIs on the US market. Clinical experience 
with these medications ranges from 3 to 20 years. All of the identified studies addressing long-term use have 
follow-up of 10 years or less (Table). Studies of longer duration are warranted. We reviewed the possible 
adverse effects of these medications. 
Gastric carcinoid. PPIs cause predictable and sustained hypergastrinemia in response to acid suppression. In 
rats, this causes enterochro-maffin-like cell (ECL) hyperplasia and carcinoid tumors, raising a safety concern in 
humans. In a nonsystematic review of 11 studies of 1800 patients who used PPIs from 6 months to 8 years, 
there were no neoplastic ECL changes or carcinoid tumors.1 Three other nonsystematic reviews support these 
findings.2-4 In a randomized controlled trial comparing efficacy and safety of rabeprazole with omeprazole for 
gastro-esophageal disease, 123 (51%) out of 243 patients completed 5 years of the study; no patients had 
neoplastic ECL changes.5 
Atrophic gastritis and gastric cancer. Atrophic gastritis with intestinal metaplasia is associated with gastric 
adenocarcinoma. Because PPIs can theoretically cause atrophic gastritis, there is a concern that this could 
lead to gastric cancer. The evidence regarding atrophic gastritis is contradictory. A nonsystematic review 
identified 1 cohort study and 1 randomized controlled trial of patients taking omeprazole from 1 to 4 years, 
which showed no association between PPI use and atrophic gastritis.1 The same review reported that another 
cohort study of patients using omeprazole for 1 year showed an increase in atrophic gastritis. None of the 
studies reviewed showed an association between omeprazole use and intestinal metaplasia or its progression 
to gastric adenocarcinoma.1 Three other nonsystematic reviews support these findings.2,3,5 The available 
evidence indicates that PPI use is not clearly associated with atrophic gastritis, or with progression from 
gastritis to metaplasia or cancer. 
Enteric infections. Because hypochlorhydria is associated with bacterial enteric infections, bacterial enteritis 
is a theoretical risk of long-term PPI use. A large case-control study of 54,461 patients using omeprazole for 1 
year showed no association with such infections.6 
Mineral malabsorption. Dietary calcium, phosphorus, magnesium, zinc, and iron depend on gastric acid for 
absorption. Two separate non-systematic reviews showed no problems with malabsorption of these 
micronutrients.1,3 
B12 malabsorption. Two nonsystematic reviews showed a decrease in vitamin B12 absorption among 
patients on high-dose (up to 80 mg of omeprazole daily), long-term PPI therapy (eg, patients with Zollinger-
Ellison syndrome).1,2 This has not been demonstrated for patients taking more typical doses of omeprazole. 
The clinical significance of this is unknown; however, the authors of these reviews suggested monitoring B12 
levels of patients on long-term, high-dose PPI therapy. 
 
TABLE 
Potential proton pump inhibitor safety concerns 
Safety concern PPI studied 
Duration 
of studies 
Evidence 
Gastric carcinoids 
Omeprazole, 
lansoprazole, 
pantoprazole, 
rabeprazole 
1–8 years 
No increased risk1-
5 
Gastric 
metaplasia/adenocarcinoma 
Omeprazole 1–5 years 
No increased risk1-
3,5 
Enteric infections Omeprazole 1 year No increased risk6 
Mineral malabsorption Omeprazole 
6 months–
2 years 
No increased 
risk1,3 
B12 malabsorption Omeprazole 10 years 
Decreased B12 
levels with high-
dose therapy1,2 
  RECOMMENDATIONS FROM OTHERS 
A Federal Drug Commission report indicates that labeling PPIs for cancer risk is not warranted.7 The American 
College of Gastroenterology and the University of Michigan Health System guidelines for treatment of 
gastroesophageal disease recommend long-term PPI therapy as an option without any warning against their 
use.8,9 
CLINICAL COMMENTARY 
No evidence of long-term adverse health effects 
from PPIs, but cost still a problem 
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Proton pump inhibitors work. They effectively treat the symptoms and reduce the 
complication involved with peptic ulcer disease. The lack of evidence suggesting any long-
term adverse health effects, even if not definitive, is very encouraging, but the cost of 
these medicines remains a problem. Both patients and third-party payers continue to 
object to their cost, and for this reason, as well as longer safety track records, less 
expensive medicines such as H2 blockers and over-the-counter antacids should be tried 
for longer-term treatment. 
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